Premium
Study of peripheral BRAF V600E mutation as a possible novel marker for papillary thyroid carcinomas
Author(s) -
Kwak Jin Young,
Jeong Jong Ju,
Kang Sang–Wook,
Park Seulkee,
Choi Jong Rak,
Park Seo–Jin,
Kim Eun Kyung,
Chung Woong Youn
Publication year - 2013
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.23195
Subject(s) - medicine , mutation , papillary thyroid cancer , thyroid , thyroid cancer , stage (stratigraphy) , pathology , population , thyroid carcinoma , cancer , gastroenterology , oncology , cancer research , biology , gene , genetics , paleontology , environmental health
Background The BRAF V600E mutation can be detected peripherally in the serum of patients with thyroid cancer. The purpose of this study was to establish the value of detecting the peripheral BRAF V600E mutation as a serum tumor marker in this population. Methods In this study, we obtained 94 serum samples from patients with papillary thyroid cancer positive for the BRAF V600E mutation in the tumor itself. The serum samples were analyzed for BRAF V600E mutation using real‐time polymerase chain reaction (PCR). Results Sixty‐seven patients (71.3%) had papillary thyroid microcarcinoma and 26 patients (27.7%) had underlying lymphocytic thyroiditis. Forty‐three patients (45.7%) were found to have stage III or stage IV thyroid cancer. None of the patients had a detectable serum BRAF V600E mutation. Conclusion We were unable to identify peripheral BRAF V600E mutations in patients with papillary thyroid cancer using real‐time PCR. Further studies will be needed to validate our results using various diagnostic methods. © Wiley Periodicals Inc. Head Neck , 35 : 1630–1633, 2013